Ermiş Sıtkı Samet
Faculty of Medicine, Balıkesir University, Tıp Fakültesi, Čagış Kampüsü, Balıkesir, Turkey.
Clin Ophthalmol. 2012;6:673-8. doi: 10.2147/OPTH.S24248. Epub 2012 May 7.
Glaucoma is a chronic disease requiring lifelong treatment. Discomfort due to medications may affect patients' quality of life and may cause poor compliance, which leads to poor intraocular pressure control. To minimize the side effects of long-term treatment, preparations with lower benzalkonium chloride concentrations, preservative-free preparations and alternative preservatives have been developed and reported to have a lower rate of side effects. Tafluprost, launched on the ophthalmic market in 2008, is a new 16-phenoxy analogue of prostaglandin F(2α), clinically used as an ocular hypotensive agent for the treatment of glaucoma and ocular hypertension. The safety and intraocular pressure-lowering efficacy of tafluprost has been demonstrated in various preclinical and clinical studies.
青光眼是一种需要终身治疗的慢性疾病。药物引起的不适可能会影响患者的生活质量，并可能导致依从性差，进而导致眼压控制不佳。为了将长期治疗的副作用降至最低，已开发出苯扎氯铵浓度较低的制剂、无防腐剂制剂和替代防腐剂，据报道这些制剂的副作用发生率较低。他氟前列素于2008年投放眼科市场，是一种新型的前列腺素F(2α)的16-苯氧基类似物，临床上用作降眼压药物，用于治疗青光眼和高眼压症。他氟前列素的安全性和降眼压疗效已在各种临床前和临床研究中得到证实。
